Member Info for BuenaVista

HurstBot is as useful to this BB as the singing bush was.

https://www.youtube.com/watch?v=aLqIWd10ccY

A message for the 🤡 that is HurstBot:

"Precision oncology is defined as the molecular profiling of tumors to identify targetable alterations. In simpler terms, it's the science of using a patient's genetics to create a treatment plan targeted to the molecular characteristics of their cancer."

https://na.geneseeq.com/precision-oncology/

In simple terms for the 🤡: pre|CISION, or more strictly written as pre|CISION™, is a trademark (a recognizable sign, design, or expression that identifies a product or service from a particular source and distinguishes it from others), part of Avacta's intellectual property, whereas the 'precision' in 'precision medicine' and 'precision oncology' is exactly as described in detail on the webpage cited above. The two things are not the same.

But no doubt HurstBot will continue to find and post irrelevant precision medicine trash.

Breast cancer was included as a possible indication in Phase 1a because such cancers are FAP-positive and common. I don't know whether any breast cancer patients were recruited. If none were, then Avacta would have zero data about the effectiveness of AVA6000 for any of the breast cancer sub-types.

I'd say the chances of Avacta developing AVA6000 for breast cancer are, for all practical purposes, zero without a partner doing the heavy lifting as many large and expensive trials would be needed.

I don't know where the idea of AVA6000 being trialled for breast cancer came from. Was it the Twatterati?

I find it best to ignore all the 💩 on Twitter.

Exactly as I predicted, the super-ramper Aldebaran, formerly the super-ramper Monkeysponge who disappeared immediately after the 13 December 'AVA6000 data reveal', disappeared on 30 September immediately after the interims business presentation. Probably bought at the low and will come back super-ramping when the share price rises ahead of some presentation event. The 30 October R&D Spotlight may be too soon but time will tell.

I hope no one was fooled by that trader's verbose shtick.

That would value the company at £582m. Do you think that is realistic?

Did CC say "during October"? There are two poster presentations in Barcelona before the R&D day so that's two bits of news in one or two announcements. Difficult to think that anything else about the pipeline could be released prior to the 30th.

Big pharma require proof in Phase 2 because the pharma industry is, despite what one might think from the mega-dollar deals but really because of the size of those deals, a conservative industry where few CEOs are prepared to stick their necks out (failure can be very unforgiving) and spend those megabucks on new areas - unless everyone else is doing it. Lemmings, if you like. So after the first major deal, as long as it doesn't exclude deals with other companies, expect the logjam to clear and deals to come thick and fast and potentially to be of increasing value.

The pipeline (30th October) will need to come with positive initial in vitro and animal study data to give it credibiity but it will also imply a huge funding requirement so I can't see that shifting the share price except temporarily.

The sale of Dx could be any time from now until... How much it will shift the share price, and in which direction, will depend on whether Avacta are seen as achieving fair, or better, value and an estimate of how long that will extend the cash runway.

What would shift the share price up would be an enthusiatic Myles McNulty Xcreation...

Given how much this share swings to overbought then oversold and back again I fully expect a recovery that will be lept on by traders and investors but the wise investors will have been buying now before that upswing fully starts.

The science is derisked. Now just for the funding.

The pipeline work started long before Alan left and I wouldn't be at all surprised if it originated and is being led by Bachovchin at Tufts, e.g. (just pulled out of the hat) https://patents.google.com/patent/WO2022094262A1/en

It's looking very much as though Cuddon's hatchet job on Avacta is going to achieve the price his paymaster wanted.

Just so long as they don't have to go back to the beginning.

Thornogson's not invested. Filter, report or ignore.

What's with the 'we', trader?

Reminds me of the St Ives School of Panting from Gloomsbury. Eggy should try that, if he isn't already doing it with TW.

If they are looking at three indications (SGC and 2 sarcomas) in Phase 1b and selecting one of those for Phase 2, then they've had all the breast cancer patients on the trial that they're going to get. There were a few but only a few. As I remember, the majority of the 'other' cancers were CRC.

"I cant believe people are selling when we have a news rich month coming up, its quite funny really ! i suppose some people just are a bit slow on the uptake !"

Well we knew that there would be news (the two posters about pipeline drugs to be presented at EORTC) and now know there will be more news (the R&D Spotlight day) in October, as well as the possibility of some really good news about revenue, but many holders won't and traders and shorters have done a good job of driving the share price down and spooking those uninformed holders.

@Bigears, I get the impression CC is using RNSes sparingly (there is a cost) and using them to combine bits of news. Releasing an RNS just to counter the Cuddon slur would have sounded defensive and so I understand why it wasn't done. However there were two bits of news during that time - nomination for the Scrips R&D in Oncology award and attendance at EORTC in Barcelona on 24 October - both of which highlighted the promise of AVA6000 and the pre|CISION platform and would have been an ideal opportunity to slip in a strong note about how AVA6000 is exceeding expectations and the clinical trial results so far are amazing for end-of-life metastasised patients who've undergone multiple lines of treatment already.

The bloke from Deutsche Bank was playing the market for the people that wanted a lower price. His entirely fictitious and malicious angle was that AVA6000 doesn't work, so the company is worthless. In which case, why 40p and not 30p or 20p? Purely because 40p was the lowest he could go without being called out as obviously, even by AIM standards in the FCA's eyes, corrupt and manipulating the market on behalf of third parties.